Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.1K
Overview
45.1K
Cross-reactivity00:42

Cross-reactivity

31.4K
Overview
31.4K
Transduction01:16

Transduction

65
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome...
65
Conjugated Proteins02:50

Conjugated Proteins

18.4K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel extracellular vesicle release pathway facilitated by toxic superoxide dismutase 1 oligomers.

Neurobiology of disease·2026
Same author

Pasteurized Milk Serves as a Passive Surveillance Tool for Highly Pathogenic Avian Influenza Virus in Dairy Cattle.

Viruses·2025
Same author

Trimeric superoxide dismutase 1 antibody as a universal biomarker for ALS.

Research square·2025
Same author

A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants.

NPJ vaccines·2025
Same author

Novel extracellular vesicle release pathway facilitated by toxic superoxide dismutase 1 oligomers.

bioRxiv : the preprint server for biology·2025
Same author

Serological Assays Reveal No Evidence of Natural SARS-CoV-2 Infection in US Cattle.

Microorganisms·2025

Related Experiment Video

Updated: Aug 15, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K

Adaptation-proof SARS-CoV-2 vaccine design.

Yashavantha L Vishweshwaraiah1, Brianna Hnath1, Brendan Rackley1

  • 1Department of Pharmacology, Penn State College of Medicine, Hershey, PA, 17033-0850, USA.

Advanced Functional Materials
|January 2, 2023
PubMed
Summary

Researchers developed novel immunogens by grafting conserved SARS-CoV-2 spike protein regions onto scaffolds. This strategy aims to create broadly protective vaccines by targeting stable, non-mutating viral epitopes.

More Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K

Related Experiment Videos

Last Updated: Aug 15, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.9K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.7K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K

Area of Science:

  • Immunology
  • Virology
  • Structural Biology

Background:

  • The SARS-CoV-2 spike protein, particularly its receptor binding domain (RBD), is a key target for neutralizing antibodies and viral entry via the ACE2 receptor.
  • Mutations in the RBD allow SARS-CoV-2 to evade immune responses, necessitating strategies for broader protection.
  • Conserved structural regions of the spike protein offer potential targets to overcome viral immune escape.

Purpose of the Study:

  • To design stable immunogens targeting conserved, non-RBD regions of the SARS-CoV-2 spike protein.
  • To develop a novel vaccine design methodology using 'epitope grafting' for rational vaccine development.
  • To assess the potential of engineered immunogens in both vaccine and diagnostic applications.

Main Methods:

  • Computational modeling and structural characterization were used to design epitope-scaffolds.
  • 'Epitope grafting' involved presenting conserved spike protein epitopes on heterologous scaffolds.
  • Immunogenicity was assessed by immunizing mice and analyzing sera for binding activity.

Main Results:

  • Engineered epitope-scaffolds accurately mimicked target spike protein epitopes structurally.
  • Immunization with designed scaffolds elicited antibodies that bound to both the scaffolds and the native spike protein.
  • The developed epitope-scaffolds demonstrated utility in diagnostic applications.

Conclusions:

  • The study presents a viable methodology for targeting conserved, non-RBD structural motifs of the SARS-CoV-2 spike protein for vaccine design.
  • 'Epitope grafting' is a promising approach for developing rational vaccines against SARS-CoV-2 and potentially other viruses.
  • The engineered immunogens show potential for broad-spectrum vaccines and diagnostic tools.